All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Global socioeconomic disparities in ALL: toxicity

Sep 22, 2023
Learning objective: After reading this article, learners will be able to cite new clinical developments in ALL.

Bookmark this article

Global socioeconomic disparities in ALL: toxicity

This series of podcasts covers global socioeconomic disparity in ALL. In this episode, the ALL Hub asked Marisa Felice, Hospital of Pediatrics SAMIC, Buenos Aires, AR and Shaun Fleming, Alfred Hospital, Melbourne, AU about the disparity in toxicities and their management in ALL, including:

  • What are the toxicities you encountered while treating patients with ALL and how did you manage them?

  • What are the barriers contributing to poor toxicity management?

Felice and Fleming discussed socioeconomic disparities in the management of toxicities in ALL across high middle-income countries (HMIC), low middle-income countries (LMIC), and within adult and pediatric populations.

Felice mentioned that diagnosis of non-frequent adverse events such as thrombosis, the management of infections given the differential access or incorrect use of antibiotics, and lack of nutritional care are some of the toxicity challenges faced in Argentina. A forum is underway for hematologists to discuss the best way to diagnose and treat complications of ALL.  

Fleming outlines that the management of toxicities in elderly patients is quite challenging, given higher rates of toxicity and lower tolerability; therefore, novel therapies are needed in Australia. Moreover, toxicities differ across populations, such as liver toxicities, pancreatitis, and thrombosis which are common in adults but rare in children; the literature and future protocols should recognize the key differences. Infections represent a major issue in HMICs, particularly among adult patients.  

More about...


Subscribe to get the best content related to ALL delivered to your inbox